References

I-157


3. Ionis Pharmaceuticals, Inc. A Study to Assess the Efficacy and Safety of IONIS-SMN Rx in Infants with Spinal Muscular Atrophy. NLM Identifier: NCT02193074.


15. De Vivo DC, Topaloglu H, Swoboda K et al. Nusinersen in Infants Who Initiate Treatment in a Presymptomatic Stage of Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From the Phase 2 NURTURE Study. 2019; 92(15).